CMVG - Clinical: Cytomegalovirus (CMV) Antibodies, IgG, Serum

Test Catalog

Test Name

Test ID: CMVG    
Cytomegalovirus (CMV) Antibodies, IgG, Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

Determining whether a patient (especially transplant recipients, organ and blood donors) has had a recent infection or previous exposure to cytomegalovirus

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Cytomegalovirus (CMV) is a member of the Herpesviridae family of viruses and usually causes asymptomatic infection after which it remains latent in patients, primarily within bone marrow derived cells.(1) Primary CMV infection in immunocompetent individuals may also manifest as a mononucleosis-type syndrome, similar to primary Epstein-Barr virus infection, with fever, malaise, and lymphadenopathy.


CMV is a significant cause of morbidity and mortality among bone marrow or solid organ transplant recipients, individuals with AIDS and other immunosuppressed patients due to virus reactivation or from a newly acquired infection.(2,3) Infection in these patient populations can affect almost any organ and lead to multiorgan failure. CMV is also responsible for congenital disease among newborns and is 1 of the TORCH infections (toxoplasmosis, other infections including syphilis, rubella, CMV, and herpes simplex virus).


CMV seroprevalence increases with age. In the United States the prevalence of CMV specific antibodies increases from approximately 36% to over 91% in adolescents between the ages of 6 to 11 and adults over 80 years old, respectively.(4)

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative (reported as positive, negative, or equivocal)

Interpretation Provides information to assist in interpretation of the test results

Positive cytomegalovirus (CMV) IgG results indicate past or recent CMV infection. These individuals may transmit CMV to susceptible individuals through blood and tissue products.


Equivocal CMV IgG results may occur during acute infection or may be due to nonspecific binding reactions. Submit an additional sample for testing if clinically indicated.


Individuals with negative CMV IgG results are presumed to not have had prior exposure or infection with CMV, and are therefore considered susceptible to primary infection.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Sera drawn very early during the acute stage of infection may have undetectable levels of cytomegalovirus (CMV) IgG. The CMV IgG assay should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings. In cases of suspected disease, submit a second sample for testing in 10 to 14 days.


The performance characteristics of this assay have not been evaluated in immunosuppressed or organ transplant recipients and have not been established for cord blood or for testing of neonates.


Immune complexes or other immunoglobulin aggregates present in patient samples may cause increased nonspecific binding and produce false-positive results.


Potential cross-reactivity for CMV with human chorionic gonadotropin, HIV IgG, multiple myeloma IgG, rheumatoid factor IgM, and Toxoplasma gondii IgG have not be ruled out.

Supportive Data

To evaluate the accuracy of the BioPlex cytomegalovirus (CMV) IgG multiplex flow immunoassay, 598 prospective serum samples submitted for routine CMV IgG testing by the VIDAS enzyme-linked fluorescence immunoassay (ELFA; bioMerieux, Durham, NC) were also analyzed in a blinded fashion by the BioPlex assay within a 24-hour period. Samples with discordant results after initial testing were repeated by both assays during the same freeze/thaw cycle. Further resolution of discrepant results was performed by using the Diamedix CMV IgG enzyme immunoassay. The results are summarized below:




BioPlex CMV IgG


















a) Both of these serum samples were negative by the Diamedix CMV IgG EIA

b) All three of these serum samples were negative by the Diamedix CMB IgG EIA

Sensitivity: 99.1% (336/339); 95% Confidence Interval (95% CI): 97.3%-99.8%

Specificity: 99.2% (254/256); 95% CI: 97.0%-100%)

Overall Percent Agreement: 98.7% (590/598); 95% CI: 97.3%-99.4%

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Soderberg-Naucler C, Khanna R, et al: Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997;91:119

2. Kusne S, Shapiro R, Fung J: Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1999;1(3):187-203

3. Rubin RH: Importance of CMV in the transplant population. Transpl Infect Dis 1999;1(1):3-7

4. Staras SA, Dollard SC, Radford KW, et al: Seroprevalence of cytomegalovirus infection in the United States, 1998-1994. Clin Infect Dis 2006;43(9):1143